MENLO PARK, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Corium, Inc. announced today that its Board of Directors has named Perry Sternberg as Chief Executive Officer. Mr. Sternberg is a senior pharmaceutical executive with commercial experience across a wide range of therapeutic areas in diverse markets. He most recently served a dual role at Shire Plc as the Head of U.S. Commercial for seven therapeutic area business units, as well as the Chief Commercial Officer/Head of the Neuroscience Division, before the recent acquisition of Shire by Takeda Pharmaceutical Corporation Limited. He brings more than 25 years of experience in the pharmaceutical and biotechnology industries with direct responsibility for the launch and commercialization of more than twenty products over the course of his career. Mr. Sternberg will succeed Peter Staple, who has served as Corium’s Chief Executive Officer since 2008 and will continue his involvement with the company as Chairman of its Board of Directors.
“I’m very excited to welcome Perry to lead Corium into the next major phase of our development,” said Mr. Staple. “He brings years of demonstrated launch success across a variety of therapeutic areas. Perry is uniquely qualified to step into the leadership role and build out the organization to commercialize our own products, starting with our lead Corplex™ Donepezil candidate for Alzheimer’s patients, and help guide the development of Corium’s pipeline.”
“I am honored to be joining the Corium team at such an important point in its history, and look forward to building on its strengths in developing and manufacturing innovative transdermal products,” said Mr. Sternberg. “Based on Corium’s pipeline of products in development, as well as the financial backing and deep industry expertise the company has from Gurnet Point Capital, we have a clear opportunity to accelerate the growth of the company and meet the needs of patients and their families.”
Before joining Shire in 2013, Mr. Sternberg served as the Vice President and General Manager of U.S. and Canada Pharmaceuticals at Bausch & Lomb. He started his pharmaceutical industry career at Merck & Co, Inc. as a sales representative and moved on to hold a series of sales and marketing roles of increasing scope at Merck & Co, Inc., Novartis Pharmaceuticals, Novartis Ophthalmics and Bausch & Lomb. Mr. Sternberg’s career therapeutic expertise has spanned across neuroscience, ophthalmics, osteoporosis, cardiovascular, genitourinary and rare diseases.
Corium, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. In November, 2018, all of Corium’s outstanding stock was acquired by an affiliate of Gurnet Point Capital. For further information, please visit www.coriumintl.com.
About Gurnet Point Capital
Gurnet Point Capital is a unique healthcare fund founded by Ernesto Bertarelli and led by Chris Viehbacher, who, together, have decades of expertise in an industry for which they share a passion, both as Chief Executives and as investors. With an initial allocation of $2 billion, GPC is investing long-term capital and supporting entrepreneurs in building a new generation of companies. Based in Cambridge, MA, its remit is global, encompassing life sciences and medical technologies. The fund invests across all stages of product development through to commercialization and does so with an approach that is a hybrid of venture and private equity investing strategies. www.gurnetpointcapital.com
Corplex™ and MicroCor® are registered trademarks of Corium, Inc.
Investor and Media Contact:
Susan M. Pietropaolo
Source: Corium, Inc.